This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.


Uniting Antibodies and Cell Therapy to Fight Cancer

Acepodia is developing potent, off-the-shelf targeted cancer cell therapies that unlock the immune system’s ability to fight both solid tumors and hematological malignancies.

Antibody-Cell Conjugation (ACC) technology uses live-cell compatible chemistry to link any tumor-targeting antibody to the surface of human immune cells. This powerful, new approach to cell therapy development has the potential to dramatically enhance the ability of oNK cells and gamma delta T cells to recognize and engage the tumor by unlocking multiple receptor signaling pathways. This could potentially allow ACC-oNK therapies to overcome the challenges that have prevented cell therapies from effectively targeting solid tumors.

Applying The ACC Approach
Highly Versatile and Broadly Applicable

Highly Versatile and Broadly Applicable

In addition to the benefits of potency conferred by ACC, its simplicity and modular “plug and play” nature could make cell therapies more accessible to patients and allows for the expansion into other indications beyond oncology and other cell lines beyond NK cells.
In the Clinic: ACC candidate for HER2-Expressing Solid Tumors

In the Clinic: ACC candidate for HER2-Expressing Solid Tumors

Acepodia’s lead clinical candidate, ACE1702, is a HER2-targeting ACC-oNK cell therapy developed for the treatment of HER2-expressing cancers including breast, endometrial and colorectal cancers.

ACE1702 is being evaluated in a Phase 1 clinical trial which is currently enrolling patients in the U.S.

Potent, Off-the-Shelf Cell Lines as the Chassis for our ACC Technology

In order to develop the most effective immunotherapies possible, Acepodia combines its ACC technology with both of its proprietary off-the-shelf NK (oNK) cells and gamma delta (γδ) T cells which are allogeneic, and specially selected for enhanced tumor engagement. ACC allows for any antibody to be conjugated to the stimulatory surface receptors of these immune cells to yield the additive effect of superior tumor targeting to its already potent and off-the-shelf biologic drug payloads.




Phase I
Phase II
HER2 Targeting, ACC-oNK Cell Therapy
Phase I ​
CD20 Targeting, ACC-γδ T Cell Therapy
Preclinical ​
PD-L1 Targeting, ACC-γδ T Cell Therapy
Preclinical ​
CD70 Targeting, ACC-γδ T Cell Therapy
Preclinical ​
We have collaborated with biopharmaceutical partners and academic institutes worldwide.